home / stock / ntra / ntra news


NTRA News and Press, Natera Inc. From 01/13/20

Stock Information

Company Name: Natera Inc.
Stock Symbol: NTRA
Market: NASDAQ
Website: natera.com

Menu

NTRA NTRA Quote NTRA Short NTRA News NTRA Articles NTRA Message Board
Get NTRA Alerts

News, Short Squeeze, Breakout and More Instantly...

NTRA - Natera Announces New Early Priority Date cfDNA Patent, Files Suit Against CareDx

SAN CARLOS, Calif. , Jan. 13, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today filed suit against CareDx for infringing its U.S. Patent 10,526,658 ("the '658 patent"). The U.S. Patent Office most recently recognize...

NTRA - Natera Launches BESPOKE CRC Study to Evaluate Outcomes in 1,000 Signatera(TM) Patients with Stage II-III Colorectal Cancer

SAN CARLOS, Calif. , Jan. 9, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA) a global leader in cell-free DNA testing, today announced a nationwide multi-center registry study called BESPOKE CRC for patients diagnosed with Stage II-III colorectal cancer (CRC). The study's o...

NTRA - Natera To Webcast Live Presentation at the 38th Annual J.P. Morgan Healthcare Conference

SAN CARLOS, Calif. , Jan. 8, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will webcast a live presentation at the 38th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Franci...

NTRA - Natera Announces Achievement of $55 Million In Pharma Contracts and Issuance of New Oncology Patents

SAN CARLOS, Calif. , Jan. 6, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced it has exceeded its 2019 goal of $40 - $50 million in cumulative total contract value (TCV) and has expanded its personalized ctDNA mini...

NTRA - Natera Receives Final Medicare Coverage for Prospera(TM) Organ Transplant Rejection Assessment Test

SAN CARLOS, Calif. , Dec. 19, 2019 /PRNewswire/ -- Natera, Inc.   (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that Medicare has finalized its local coverage determination (LCD) to provide insurance coverage for the Prospera donor-derived cell-fr...

NTRA - Natera Inc.: Multiple Catalysts In 2020 For More Upside

Natera Inc. (NASDAQ: NTRA ) with a market cap of $3 billion is a medical diagnostics company focusing on genetic testing across a range of applications. The company is currently commercializing a number of reproduction and prenatal-related DNA tests that are already industry-leading while ex...

NTRA - Panorama Publication Demonstrates Utility of Measuring Individual Fetal Fractions in Twin Pregnancies

SAN CARLOS, Calif. , Nov. 27, 2019 /PRNewswire/ --   Natera, Inc.   (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced results of a study published in the  Journal of Prenatal Diagnosis  which demonstrated that measuring individual fetal frac...

NTRA - Healthcare On The March

Healthcare Pulse Healthcare is at its all-time highs eclipsing the highs recorded a year earlier during the Oct-Nov 2018 period. Of course, if one looks at the broader market which has been recording such all-time highs since the summer of this year, it's understandable to shrug shoulders ...

NTRA - Best-Performing Small-Cap Stocks YTD: November 2019

This article takes a look at the best-performing small-cap stocks with a list that presents an interesting group of emerging companies that are fast-growing or have attracted significant bullish sentiment based on a strong outlook. We take the Russell 2000 ( IWM ) constituents as our univers...

NTRA - Natera, Inc. 2019 Q3 - Results - Earnings Call Presentation

The following slide deck was published by Natera, Inc. in conjunction with their 2019 Q3 earnings Read more ...

Previous 10 Next 10